Voxilaprevir
Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir.
≈ 2 min read
Voxilaprevir. encyclopegia.org, snapshot enwiki-001370850150. /a/voxilaprevir
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir.[2] The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.[3]
On 18 July 2017, Vosevi was approved by the US Food and Drug Administration.[4]
References
edit edit source- ^ "voxilaprevir_msds". Wikipedia revision 1370850150, retrieved 2026-11-21
- ^ Heo YA, Deeks ED (April 2018). "Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C". Drugs. 78 (5): 577–587. doi:10.1007/s40265-018-0895-5. PMID 29546556. S2CID 4395880. Wikipedia revision 1370850150, retrieved 2026-11-21
- ^ "Summary of opinion: Vosevi" (PDF). European Medicines Agency. 22 June 2017. Archived from the original (PDF) on 18 June 2018. Retrieved 27 June 2017. Wikipedia revision 1370850150, retrieved 2026-11-21
- ^ FDA approves Vosevi for Hepatitis C Wikipedia revision 1370850150, retrieved 2026-11-21
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
Text derived from https://en.wikipedia.org/w/index.php?oldid=1370850150 under CC BY-SA 4.0; modifications have been made.